Vical and Merck are investigating vaccines against hepatitis B which use Vical's patented naked DNA technology. Both therapeutic and prophylactic vaccines are under development [177132], [268397]. The technology, and subsequent collaboration, stems from the observation by Vical that by directly injecting exogenous cDNA into muscle tissue, protein is expressed which gives rise to a strong immune response and protective immunity [163222].
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
naked dna
8
technology evaluation
4
evaluation naked
4
dna vical
4
vical merck
4
merck investigating
4
investigating vaccines
4
vaccines hepatitis
4
hepatitis vical's
4
vical's patented
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!